Abstract:OBJECTIVE:The purpose of this phase I/II study is to investigate the safety/toxicity profile of weekly administration of docetaxel in combination with cisplatin for the chemo-naive patients with advanced non-small cell lung cancer (NSCLC), and to evaluate the efficacy of this regime. METHODS:In phase I trial, 15 patients were included. IV infusion of escalating doses of docetaxel consisting of four levels from 25 to 40 mg/m2 (25, 30, 35, 40 mg/m2) on D1, 8, 15 and cisplatin of 75 mg/m2 on D1 was administered. The regime was repeated every 4 weeks. Blood samples were obtained on D1, 15 in the first cycle to measure the PK. Dose limiting toxicity (DLT) was determined in cycle 1 and defined as any grade 3 non-hematologic toxicity which could not be reverted into grade less than grade 2 within 4 days or any grade 4 hematologic toxicity. Eighty-three patients completed their phase II study with administration of docetaxel at a dose of 35 mg/m2 based on the data of phase I trial. RESULTS:In the phase I trial, grade 3/4 neutropenia was mainly observed in patients who received docetaxel of 40 mg/m2 (level 4) with one patient suffering from an infection signifying dose limiting toxicity (DLT). Non-hematological toxicities including nausea/vomiting, alopecia, fluid retension and asthenia were tolerable. Based on these data, the maximum tolerence dose (MTD) did not reach the level of weekly giving docetaxel at a dose of 40 mg/m2 in combination with cisplatin 75 mg/m2 every 4 weeks. The pharmacokinetic/dynamics results There was no statistically significant difference between clearance value among the 4 dose levels of docetaxel from 25 to 40 mg/m2 when measured by Cmax and AUC. The pharmacokinetics of docetaxel was not influenced by the presence of co-administration of cisplatin when compared D1 with D15 as based on CmaxN, AUCN and CL. In the phase II trial, totally 83 patients received 216 cycles of chemotherapy. One CR (complete response) and 22 PR (partial response) were achieved with an objective response rate of 27.7% in this series and 30.7% in the evaluable patients. The 1-year survival was 48.6% with a median survival of 10.7 months (range: 3-34 months). Hematologic toxicities were the major side effects, though most were mild; grade III/IV neutropenia developed in 15%. The common non-hematologic toxicities were nausea, vomiting and asthenia. CONCLUSION:Weekly consecutive administration of docetaxel on D1, 8, 15 for 3 weeks plus cisplatin on D1 is tolerable and effective with minimal myelosuppression in chemo-naive patients with advanced NSCLC.

Phase II Study of Carboplatin Combined with Weekly Docetaxel in Patients with Advanced Non-Small Cell Lung Cancer

A Study of Weekly Docetaxel and Carboplatin As First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer.

Phase II Study of Gemcitabine and Carboplatin in Patients with Advanced Non-Small-cell Lung Cancer.

[Phase I/II clinical trial of weekly administration of docetaxel plus cisplatin for advanced non-small cell lung cancer].

Clinical Study of Weekly Docetaxel As Second Line Therapy to Non-Small Cell Lung Cancer

Phase II clinical trial on docetaxel in the treatment of non-small-cell lung cancer

Phase II Trial of a 2-H Infusion of Gemcitabine Plus Carboplatin As First-Line Chemotherapy for Advanced Non-Small-cell Lung Cancer

[A Randomized Phase II Trial of Docetaxel and Doxorubicin in Treatment for Patients with Non-Small-cell Lung Cancer Who Have Failed Previous Platinum-Based Chemotherapy].

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Clinical Effects of Paclitaxel-Carboplatin (TC) Alone or with Endostatin for Advanced Non-Small Cell Lung Cancer (NSCLC).

First Line Chemotherapy with Weekly Docetaxel and Cisplatin in Elderly Patients with Advanced Non-small Cell Lung Cancer: A Multicenter Phase II Study

A Phase II Trial of Concurrent Chemoradiotherapy with Weekly Paclitaxel and Carboplatin in Advanced Oesophageal Carcinoma.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer

Concomitant Chemoradiation Therapy Phase II Study Comparing Pemetrexed/Carboplatin with Paclitaxel/Carboplatin in Patients with Unresectable Stage III Non-small Cell Lung Cancer

Phase I Study of Docetaxel Combined with Carboplatin in Patients with Non-Small Cell Lung Cancer

A Phase II Trial of Chemoradiation Using Weekly Docetaxel for High-Risk Postoperative Oral Squamous Cell Carcinoma Patients

Safety and Efficacy of Dendritic Cell-Based Immunotherapy (dcvac/luca) Combined with Carboplatin/pemetrexed for Patients with Advanced Non-Squamous Non-Small-cell Lung Cancer Without Oncogenic Drivers

Every-2-week docetaxel plus platinum In advanced non-small cell lung cancer: response rate and quality of life assessment

A Randomized Phase Ⅱ Trial of Docetaxel/ Ifosfamide Regimen Versus Single-Agent Docetaxel in Second-Line Treatment of Advanced Non-Small-cell Lung Cancer

1376P Anlotinib Combination with Docetaxol for Patients with Previously Treated Advanced Non-Small Cell Lung Cancer: A Phase II, Single-Arm Trial

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.

[Combination of Docetaxel and Cisplatin in the Treatment of Advanced Non-Small Cell Lung Cancer].